Anergen and Sunol Molecular Corp. Partner on Key Technology for Multiple Sclerosis Treatment

Anergen, Inc. has announced a significant partnership with Sunol Molecular Corp. to develop a treatment for multiple sclerosis. The collaboration has led to the creation of a novel, recombinant form of a major histocompatibility complex class II (MHC-II) molecule, which is a crucial component of Anergen's proprietary platform technology, AnergiX. This innovative molecule will be used in preclinical evaluations alongside Anergen's native production process, aiming to improve treatment outcomes for patients with multiple sclerosis. Anergen is already conducting a phase I clinical trial for its native HLA-DR2:MBP-peptide complex, which is expected to be completed later this year. This new partnership underscores the companies' shared commitment to advancing immunotherapeutic treatments for autoimmune diseases.

Key Takeaways:

• Anergen and Sunol Molecular Corp. have entered into a license agreement to develop a recombinant form of a MHC-II molecule for the treatment of multiple sclerosis.
• The partnership resulted from a research collaboration initiated last year, which explored the use of Sunol's recombinant expression technology for producing human MHC molecules.
• Anergen aims to leverage this technology to enhance its proprietary AnergiX platform, currently being tested in a phase I clinical trial for multiple sclerosis.
• Sunol's approach provides Anergen with a choice in production methodology, potentially offering improved pharmacokinetic and economic advantages.
• The companies anticipate that the relatively low production cost and improved stability of the recombinant molecule will significantly contribute to Anergen's commercialization efforts for the product.
• Anergen is focused on advancing treatments for autoimmune diseases, and this partnership highlights its commitment to innovative research in this area.
• Sunol Molecular Corp. is a biopharmaceutical company with a range of agents under development for various diseases, including autoimmune diseases, life-threatening infectious diseases, cancer, and cardiovascular disorders.

Statistics:

• Anergen's phase I clinical trial for its native HLA-DR2:MBP-peptide complex is expected to be completed by the end of this year.
• The recombinant molecule developed through this partnership is expected to offer improved stability and reduced production costs compared to the native production process.
• Anergen has a focus on autoimmune diseases, with its proprietary AnergiX platform aiming to selectively interrupt antigen presentation or inactivate T cells in the immune system.

Sources:

• PRNewswire
• Anergen, Inc.
• Sunol Molecular Corporation
• Form 10-K for fiscal years 1996 and 1997
• Form 10-Q reports